Anvisa identifies non-standard points at Sinovac factory in China, says Veja – Money Times



[ad_1]

CoronaVac
The Health Ministry has said that all vaccines, as long as they are registered by Anvisa, can be incorporated into the plan (Image: Reuters / Amanda Perobelli)

The National Sanitary Surveillance Agency (Anvisa) would have indicated a considerable number of points outside the standards required in the Brazil after last week’s inspection at the Sinovac, in China, which is producing the vaccine CoronaVac, according to the Veja magazine website.

The flaws, according to the magazine, would be mostly minor problems, but there are more relevant points that must be corrected for CoronaVac to obtain certification in Brazil.

The Butantan Institute, linked to the São Paulo government, is testing CoronaVac in the country and will be responsible for the local production of the immunizer.

Even before the registration with Anvisa, the state governor, João Doria, has already announced the vaccination against Covid-19 in São Paulo as of January 25 and still wants to obtain the vaccine in the national immunization plan, despite the resistance president’s public Jair bolsonaro, his political opponent, to the adoption of the Chinese vaccine.

The Health Ministry has said that all vaccines, as long as they are registered by Anvisa, can be incorporated into the plan.

In a note, Anvisa did not confirm the content of the information published by Veja.

“At the closing meeting of Anvisa’s technical inspection, the works are closed, citing the findings of the inspection. Communication is done with the Butantan Institute in the formal terms of the inspection process. The issue is a priority for Anvisa, we are acting focused on promoting access to vaccines in Covid-19. Finally, we do not confirm what is stated in the report. We only recognize the formal channels of information with the Butantan Institute ”, he said.

Butantan, also in a note, did not give details of the communication with Butantan and said it followed the Anvisa audit at the Sinovac plant. The institute said that “it will continue to contact the control body with the aim of rapid registration of the vaccine in the country.”

“Inspections like the one carried out last week are common in the pharmaceutical industry and are intended to attest to good manufacturing practices,” he said.

[ad_2]